Lindsay Landers, DO
Family Medicine · Andover, KSNPI 1407872708
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 120 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 10.7% — the pattern of someone who eats at a lot of different presentations.
Across 120 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$220
- Astellas Pharma US Inc$192
- AstraZeneca$191
- GSK$188
- AbbVie$184
- Pfizer$181
- plus $890 from 21 others
Across 3 payments — averaging $11,956 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$36K
What the payments were for
- Food & beverage$2,046100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 15 | $220 |
| Astellas Pharma US Inc | 13 | $192 |
| AstraZeneca | 6 | $191 |
| GSK | 12 | $188 |
| AbbVie(2 entities) | 11 | $184 |
| Pfizer | 12 | $181 |
| Amgen | 9 | $141 |
| Abbott | 8 | $124 |
| Mckesson Medical-surgical, Inc. | 1 | $94 |
| Medtronic | 3 | $71 |
| Bayer | 4 | $63 |
| Merck | 4 | $55 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $47 |
| Lilly USA, LLC | 3 | $41 |
| Boehringer Ingelheim | 2 | $34 |
| Nevro Corp. | 1 | $28 |
| Amarin Pharma, Inc. | 2 | $28 |
| Johnson & Johnson | 2 | $26 |
| Neos Therapeutics, LP | 1 | $23 |
| Insulet Corporation | 1 | $19 |
| Dexcom, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $13 |
| Biohaven Pharmaceuticals, Inc. | 1 | $12 |
| Novartis | 1 | $12 |
| Strongbridge US Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BREZTRI$125
How this compares
$2,046 in reported general payments places this provider in the 75th percentile of 1,469 family medicine providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 65 | $71,890 |
| EliquisApixaban | 54 | $42,358 |
| JardianceEmpagliflozin | 37 | $30,523 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 35 | $22,382 |
| JanuviaSitagliptin Phosphate | 20 | $19,114 |
| MounjaroTirzepatide | 16 | $17,093 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $10,433 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 32 | $7,009 |
| GemtesaVibegron | 13 | $6,316 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $2,781 |
| Boostrix TdapDiphth,pertuss(Acell),tet Vac | 37 | $2,521 |
| Gabapentin | 107 | $1,556 |
| ValacyclovirValacyclovir Hcl | 20 | $1,453 |
| Duloxetine Hcl | 44 | $1,453 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 51 | $1,372 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $220 | $71,89065 claims |
| PfizerEliquis | $181 | $42,35854 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $188 | $39,82484 claims |
| Boehringer IngelheimJardiance | $34 | $30,52337 claims |
| MerckJanuvia | $55 | $19,11420 claims |
| Lilly USA, LLCMounjaro | $41 | $17,09316 claims |
| AbbVieSynthroid | $184 | $73314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,469 family medicine providers in Kansas.
Other family medicine in Andover
- Kari ClouseAndover$12K
- Stephen LemonsAndover$11K
- Christopher MeyerAndover$10K
- Bradley HarrisonManhattan$314K
- Mila MeansWichita$241K
- Scott AveryJunction City$195K
- Kent KiracofeManhattan$189K
- Terry McGeeneyLeawood$147K
- Cole GillenwaterWichita$62K
- David StricklandLawrence$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.